Axsome Looks Good On Multiple Catalysts: Fast Track Designation Eases Liquidity Concerns

Axsome Therapeutics Inc. (AXSM) has multiple catalysts coming up in the near future as it has two main drug candidates under Phase 3 testing for multiple conditions. The stock has shown strength as it gained over 12 percent in the past one month.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.